Skip to main content

Table 2 Summary of received treatments for Hematological Malignancies at the onset of COVID-19

From: COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

  n %
Last/ongoing treatment strategy before COVID-19
Immunochemotherapy 857 22.5
Targeted therapya 607 16.0
Conventional chemotherapy 597 15.7
No treatment 538 14.1
Palliative/supportive measures 226 6.0
Immunomodulators 218 5.7
Allogeneic HSCT 173 4.6
Anagrelide/Hydroxyurea 145 3.8
Hypomethylating agents 141 3.7
Immunotherapy only 125 3.3
Autologous HSCT 74 1.9
Unknown 41 1.1
Other 28 0.7
CAR-T 21 0.6
Radiotherapy 10 0.3
Summary of received treatmentb
Chemotherapy 3178 83.6
 In the last month 1979 52.1
 In the last 3 months 523 13.8
 Treatment ended > 3 months 631 16.6
 Not stated 45 1.2
Radiotherapy 186 4.9
Allogeneic HSCT 265 7.0
Autologous HSCT 292 7.7
CAR-T 24 0.6
Other strategies 150 3.9
No treatment 538 14.2
  1. HSCT Hematopoietic stem cell transplantation, CAR-T chimeric antigen receptor T-cell therapies
  2. aBortezomib, ibrutinib, idelalisib, ruxolitinib, TKI (tyrosine kinase inhibitors), and venetoclax
  3. bData can be super-additive